Iterum Therapeutics reports Q4 adjusted EPS (52c) vs (27c) last year

"We made significant progress in 2022 to move the clinical development of oral sulopenem forward leading to a potential resubmission of our new drug application next year," said Corey Fishman, Iterum’s Chief Executive Officer. "Enrollment in our REASSURE trial, which is being conducted under a Special Protocol Assessment agreement with the U.S. Food and Drug Administration, is expected to be completed in the first half of 2024."